AlphaCrest Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

AlphaCrest Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,862	Closed	-$2.51M	–	583
2022 Q3	$2.51M	Buy	18,862 +11,089	+143%	+$1.69M	0.15%	148
2022 Q2	$1.21M	Buy	+7,773	New	+$1.2M	0.06%	579
2022 Q1	–	Sell	-17,631	Closed	-$2.25M	–	1330
2021 Q4	$2.25M	Buy	17,631 +4,942	+39%	+$649K	0.08%	361
2021 Q3	$1.65M	Buy	12,689 +7,684	+154%	+$1.16M	0.09%	387
2021 Q2	$889K	Sell	5,005 -324	-6%	-$56.1K	0.04%	722
2021 Q1	$876K	Buy	+5,329	New	+$877K	0.05%	554
2020 Q3	–	Sell	-5,448	Closed	-$601K	–	1145
2020 Q2	$601K	Sell	5,448 -8,748	-62%	-$967K	0.1%	310
2020 Q1	$1.42M	Buy	14,196 +6,910	+95%	+$893K	0.17%	158
2019 Q4	$1.09M	Sell	7,286 -10,260	-58%	-$1.4M	0.09%	312
2019 Q3	$2.25M	Buy	17,546 +10,903	+164%	+$1.46M	0.14%	189
2019 Q2	$947K	Buy	6,643 +1,225	+23%	+$165K	0.08%	424
2019 Q1	$775K	Buy	5,418 +2,348	+76%	+$306K	0.12%	278
2018 Q4	$381K	Buy	+3,070	New	+$455K	0.11%	348

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

AlphaCrest Capital Management's JAZZ Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2022, closing a stake of 18,862 shares — an estimated $2.51M sold.

AlphaCrest Capital Management first reported a position in JAZZ in Q4 2018 and held it in 13 quarters. The position peaked at $2.51M in Q3 2022. 486 funds tracked by Wall St. Rank hold JAZZ as of Q4 2022.

AlphaCrest Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 18,862 Jazz Pharmaceuticals shares in Q4 2022, an estimated $2.51M.
AlphaCrest Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 13 quarters.
AlphaCrest Capital Management's Jazz Pharmaceuticals position peaked at $2.51M in Q3 2022.
486 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.